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                                             ABSTRACT 
                                            INTRODUCTION 
Diabetes mellitus, one of the important non communicable diseases in our 
country and has become major health concern in recent times. Microvascular 
disease is a common complication in type 2 diabetes and diabetic retinopathy 
(DR) and nephropathy represent  leading causes of visual impairment and end 
stage renal disease respectively in adults of both developed and developing 
world.  
                  Patients with type 2 diabetes may have Diabetic Retinopathy without 
microalbuminuria. Various  studies have shown risk factors for DR that include 
hypertension, longer duration of diabetes and anemia. This has been supported 
by several studies reporting 10‑30% prevalence of DR in  type 2 diabetes with  
normoalbuminuria. Hence, early identification and correction of these predictors 
are necessary to avoid sight threatening complications due to diabetic 
retinopathy. 
                                    AIMS AND OBJECTIVES 
To estimate the prevalence of  Diabetic Retinopathy in patients with Type 2 
Diabetes Mellitus who have normoalbuminuria. 
To study the predictors  ( Anemia, Duration of  Type 2 Diabetes Mellitus, 
Hypertension) of  Diabetic Retinopathy in patients with normoalbuminuria. 
 
MATERIALS  AND  METHODS 
STUDY POPULATION: 
 This study was conducted among 100 patients with Type 2 Diabetes 
Mellitus attending Department of General Medicine  in Govt. Rajaji Hospital, 
Madurai. 
STUDY PROTOCOL: 
This study is done in 100 type 2 diabetes mellitus patients . 
Patients are first performed renal function test and microalbumin in urine. 
Patients with normal renal function test and normoalbuminuria are selected. 
Then they undergo haemoglobin estimation, measurement of blood pressure 
and history of duration of type 2 diabetes mellitus are elicited. 
Now the patient undergoes fundus examination and screening for diabetic 
retinopathy is done. 
Then the prevalence  of diabetic retinopathy and  the predictors of diabetic 
retinopathy in patients with normoalbuminuria are calculated.  
                                                      
 
 
 RESULTS:   
In our study, the diabetic retinopathy estimated prevalence  in patients with 
normoalbuminuric type  2 diabetes mellitus  is around  40%. Hence in 
normoalbuminuric  type 2 diabetes individuals, presence of other predictors like 
anemia (Hb < 8 gms), systemic hypertension and longer duration of diabetes 
can identify the individuals with diabetic retinopathy which was statistically 
significant in our study.  
CONCLUSIONS: 
               In patients of type 2 DM, inspite of normoalbuminuria diabetic 
retinopathy is very much common. Absence of albuminuria should not be the 
criteria to defer for screening of diabetic retinopathy. Various predictors for the 
determination of DR are the estimated levels of haemoglobin,  diabetes 
duration, and associated systemic hypertension.  
               . Hence, even in type 2 diabetes patients with normoalbuminuria, 
presence of other predictors like low haemoglobin, systemic hypertension and 
longer duration of diabetes can identify high risk individuals who develop 
diabetic retinopathy.                                
KEYWORDS: Type 2 Diabetes Mellitus, Normoalbuminuria, Diabetic 
Retinopathy, Anemia, Systemic Hypertension, Longer duration of Diabetes. 
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INTRODUCTION 
 
      Diabetes mellitus, one of the important non communicable diseases 
in our country and has become major health concern in recent times. 
Microvascular disease is a common complication in type 2 diabetes and 
diabetic retinopathy (DR) and nephropathy represent  leading causes of visual 
impairment and end stage renal disease respectively in adults of both 
developed and developing world.  
                  Patients with type 2 diabetes may have Diabetic Retinopathy 
without microalbuminuria. Various  studies have shown risk factors for DR 
that include hypertension, longer duration of diabetes and anemia. This has 
been supported by several studies reporting 10‑30% prevalence of DR in  type 
2 diabetes with  normoalbuminuria. 
         Higher  blood pressure was found to be  independent risk factor for 
Diabetic Retinopathy. Anemia was found to be an another risk factor. Anemia 
patients were  develop DR more frequently than individuals without  anemia,  
because of   retinal hypoxia due to anemia. 
                  Anemia identification and management is important in the 
individuals  of diabetic retinopathy. In anemic patients with (Hb<8g/dl) and 
diabetes mellitus, correction of anemia cause good improvement in diabetic 
retinopathy. Management of anemia causes better  tissue oxygenation and 
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leads to substantial decrease in VEGF synthesis, which improves the hyper 
permeability and new vessel changes are inhibited. 
                 Anemia is related to the development of DR and  as a risk factor for 
the deterioration of DR. Hence the evaluation and treatment of anemia should 
be a part of the follow up visits in DM patients. 
                 Patients with longer duration of diabetes have high risk of 
developing diabetic retinopathy due to chronic hyperglycaemic state. In  
diabetic individuals  with normoalbuminuria, identifying other predictors like 
anemia, systemic hypertension and longer duration of diabetes may help 
finding the presence of diabetic retinopathy. Hence, early identification and 
correction of these predictors are necessary to avoid sight threatening 
complications due to diabetic retinopathy.  
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       AIM  OF  THE  STUDY 
 
To estimate the prevalence of  Diabetic Retinopathy in patients with Type 2 
Diabetes Mellitus who have normoalbuminuria. 
To study the predictors  ( Anemia, Duration of  Type 2 Diabetes Mellitus, 
Hypertension) of  Diabetic Retinopathy in patients with normoalbuminuria. 
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REVIEW OF LITERATURE 
 
                         Diabetes,  literally meaning “siphon,” to explain “liquefaction 
of the flesh and bones into urine”. In 1674, Thomas Willis, and  professor of  
the natural philosophy at Oxford, discovered  that the urine of individuals with 
diabetes was sweet by tasting. This was actually  rediscovery, previously by an 
ancient Hindu document by Susruta in India in about 400 B.C. had described  
diabetic syndrome  characterized by the “honeyed urine”.  
.                  Willis could not able to  pinpoint the chemical nature of the 
“sweet” substance, because  variety of different chemical substances were  
equally sweet to the sense of taste. It was Matthew Dobson of Manchester, 
England,  demonstrated, in 1776, that persons with diabetes actually excrete 
sugar in their  urine. After boiling urine to dryness, he found  that the residue, a 
crystalline material, had the appearance and taste of “brown sugar”.  
                           In the  majority of patients with type 2 diabetes, there was  no 
single genetic defect found  for  this process. Thus, the  combination effects of 
multigenic, heterogeneous, complex, and related causes my result in the 
disease.. 
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                In a very  few  individuals with monogenic causes of  type 2 
diabetes, inheritance of the   two mutant genes from both parents or autosomal 
dominant inheritance were  responsible. Despite these  genetic heterogenicity, 
a consistent phenotype becomes manifested when the disease condition 
develops in an individual , characterized by the following 
  
1. Impairement in the  secretion of insulin. 
2. Resistance due to insulin action. 
3. Increased glucose production in the liver, due to  increased gluconeogenesis 
and  glycogenolysis.  
 
              Many  factors were  involved in the reduction  in β-cell function, 
including  dietary indiscretion causing progressive exhaustion of β cells, 
prolonged glucose toxicity, and preprogrammed genetic abnormalities in the  
β-cell function. Predominantly, it is the progressive β-cell deterioration which  
results in  worsening of  the hyperglycemic state in the type 2 diabetic 
individuals.  
               The majority of  type 2 diabetic patients are hyperinsulinemic and 
were overweight at the time of diagnosis. The subsequent conversion from the 
state of  impaired glucose-tolerant  to type 2 diabetes is influenced by 
concomitant medical conditions, distributions of the  body fat, degree of  
obesity, ethnicity, sedentary lifestyle, and  aging. Thus, one can find  that the 
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type 2 diabetic patient is at the end of a progressive triad of metabolic defects 
whose interrelationships directly affect the natural history and progression  of  
the disease. 
 
                      Illnesses related to diabetes causes large number of 
hospitalizations due to cardiovascular and renal diseases. At the time of initial 
diagnosis itself, many patients have complications due to both microvascular 
and macrovascular related problems.This deprives patients from primary 
prevention of microvascular complications. So, primary prevention is better 
than secondary prevention.  
                   According to the World Health Statistics 2012, every 10 th 
individual  is diabetic. In 2012 , 371 million had diabetes. It will increase to 
552  million by 2030. Low and middle income countries people constitute 
about  80%.Most people are in the age of  40 to 59 years.  
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DIABETES: THE INDIAN SCENARIO 
                  According to WHO ( World Health Organization), there  were 
about 32 million diabetics in 2000. According to International Diabetes 
Federation (IDF), estimated diabetics in 2030 will be around 121 million. 
There are about 62.4 million diabetics and 77 million prediabetics in India in 
2011.  
                  There are also many number of undiagnosed diabetics in India 
shown by various studies. Through various studies shown that around 50% of 
Indian diabetics have poor glycemic control. Data from CUPS (Chennai Urban 
Population Study) and CURES (Chennai Urban Rural Epidemiology Study ) 
estimates the diabetic related complications.  
DEFINITION 
             Factors opposing the  action of insulin or the lack of insulin leads to 
the occurrence of diabetes. This results in hyperglycemia because of 
inadequate insulin action. When there is absolute lack of insulin, it leads to rise 
in the level of ketone bodies resulting in ketosis. 
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PATHOPHYSIOLOGY 
             In the early stages pancreatic beta cells over stimulated for 
compensating for insulin resistance. During the course of time, beta cells get 
exhausted due to hyperstimulation  causing the blood glucose levels to rise 
leading to diabetes. 
            Normally, after meals glucose disposal occurs through tissues like brain 
which can utilize the glucose independently, followed by splanchnic uptake. 
The remaining glucose utilization occurs in insulin dependent tissues like 
adipose tissue and muscles. 
             In type 2 diabetes, the normal balance between uptake of glucose by 
tissues and endogenous glucose production following ingestion of glucose is 
disrupted. 
              Beta cell dysfunction plays a crucial role in type 2 diabetes. Beta cells 
are in constant state of changing dynamics, with regeneration from islets and 
corresponding apoptosis. This state of apoptosis and islet neogenesis gets 
altered due to numerous factors like: 
1.Genetic susceptibility 
2.Increasing age 
3.Glucotoxicity 
4.Insulin resistance 
5.Reduced incretin effect 
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6.Lipotoxicity 
7.Hexosaminases 
8.Amylin 
          The above mentioned factors lead to failure of beta cells. Rising blood 
glucose values with the background of beta cell failure  leads to inadequate 
insulin secretion. Environmental factors like obesity, gender and diet also lead 
to genetic susceptibility causing hyperglycaemic state. 
            Beta cell failure along with insulin resistance in liver and muscle is 
termed as “The Triumvirate” by De Fronzo. Insulin resistance leads to further 
decline in insulin sensitivity, poor metabolic control and hyperglycemia. 
              Most important causes for  the development of insulin resistance are 
sedentary life style and obesity. Insulin resistance is due to the presence larger 
amount of abdominal fat in diabetics. Large number of proinflammatory 
cytokines are released because of adiposity which include  
                   1.Interleukins 6 and 8 
                  2.Monocyte Chemoattractant protein 1 
                  3. Tumour Necrosis Factor alpha 
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Single Nucleotide Polymorphisms  are associated with insulin resistance and 
beta cell dysfunction. Around 40 independent loci are associated with high risk 
of type 2 diabetes. 
 
Diabetogenic Gene- Relatively specific and essential genes causing diabetes in 
an individual. 
Diabetes related  genes- Non specific and not only limited to diabetics. 
Combination of both diabetogenic genes and diabetes related genes with the 
environmental factors leads to diabetes. 
 
DIAGNOSTIC CRITERIA 
Random blood sugar more than 200 mg/dl( >11.1 mmol/L) with symptoms of 
diabetes 
                                       Or 
Fasting blood glucose level more than 126 mg/dl(>7 mmol/L) 
                                      Or 
HbA1C > 6.5% 
                                    Or 
After oral glucose tolerance test , 2 hour blood glucose more than 200 
mg/dl(>11.1 mmol/L) 
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RISK FACTORS 
1. Obesity (BMI > 25) 
2.History of cardiovascular disease 
3.Polycystic ovary syndrome or acanthosis nigricans 
4.Previous Gestational Diabetes Mellitus history or delivery of baby weight 
more than 4 kg 
5.Systemic Hypertension > 140/90 mmHg 
6.HDL cholesterol < 35 mg/dl 
7.Triglycerides > 250 mg/dl 
8.Previous History of  Impaired fasting glucose, Impaired glucose tolerance, or 
HbA1C of 5.5 to 6.5 % 
9.Sedentary lifestyle 
10.Diabetes mellitus history in family members 
11.Race/Ethnicity – African American, Native American, Asian American, 
Pacific Islander  
12.Physical inactivity 
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PATHOGENESIS 
 Hyperglycemic state causes extensive tissue damage  at the tissue level. 
Abnormal glucose tolerance causes  damage to signalling and critical  
pathways at the cellular level. Various ways through these pathways activated 
are :  
A. Hyperglycemic state leading to direct toxicity. 
B. Hyperglycemic state causing release of metabolic  derivatives and their by-
products.   
C. Continuous effects on special signaling pathways at the cellular level . 
Complications of  Type 2 Diabetes mellitus at the cellular level by various  
pathways are: 
1. Aldose reductase overactivity.  
2. Electron transport chain in the mitochondria causing overproduction of 
superoxide anions which leads to activation of hexosamine pathway . 
3. Formation of Advanced Glycation End Products . 
4.Reactive oxygen intermediates causing increased oxidative stress. 
5. Isoforms of protein kinase C gets activated. 
6. Polyol pathway activation . 
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AMERICAN DIABETES ASSOCIATION 
CLASSIFICATION OF DIABETES 
MELLITUS 
The American Diabetes Association divides diabetes into five different classes. 
They are :  
1. Gestational diabetes. 
2.  Malnutrition-associated diabetes 
3. Diabetes associated due to other factors like drugs, chemicals. 
4. . Type 2 diabetes. 
5. Type 1 diabetes. 
CHRONIC COMPLICATIONS OF DM 
The chronic complications of  DM affecting  many of the  organ systems and 
are responsible for the majority of morbidity and mortality due to the disease. 
Chronic complications of  DM are of two types : 
1. Complications due to Vascular problems.   
2. Complications due to nonvascular  Problems. 
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The vascular complications of  DM are further subdivided into macrovascular 
complications and microvascular complications. 
1.Microvascular complications   
          A. Diabetic Neuropathy  
          B. Diabetic Retinopathy           
          C. Diabetic Nephropathy 
 
2.Macrovascular complications  
         A. Cerebrovascular disease          
         B. Coronary Heart Disease (CHD) 
         C. Peripheral Arterial Disease (PAD) .  
Nonvascular complications which not as common as vascular complications  
include problems such as  
               A. Skin changes 
               B. Gastroparesis   
               C. Infections 
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 Hearing loss may occur in the long term.  Impaired mental status in the older 
age group is not  very well studied. 
Longer the duration of diabetes leads to the high chances for developing 
chronic complications due to persistent hyperglycemia. They usually will  
become manifest in the second and third  decades of hyperglycemia. Most 
individuals with type 2 DM have complications at the time of diagnosis due to 
symptom less period of hyperglycemia. 
Longer the duration of chronic hyperglycemia, more chances of developing  . 
microvascular complications  due to type 1 and type 2 DM. Most studies 
proved that whenever there is very good control of blood glucose, 
complications such as neuropathy, retinopathy and nephropathy can be 
prevented. Other not completely studied  factors may also  influence the 
development of complications.  
 Some individuals even after long-standing DM, will  never develop 
retinopathy or nephropathy. This shows that there are still some influences due 
to genetic predisposition which is responsible to develop such complications. 
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Unlike microvascular complications, the chances of developing macrovascular 
complications due to chronic hyperglycemia is not very much conclusive. But 
mortality and morbidity due to coronary heart events are high in diabetic 
individuals than in non diabetics.  
 HbA1C and postprandial plasma glucose values   very well correlate with 
such events. Other influences such as hypertension and dyslipidemia also play 
crucial  roles in macrovascular complications. 
Chronic complications of diabetes include 
1. Macrovascular  complications  
2. Microvascular complications  
3. Other complications 
MICROVASCULAR COMPLICATIONS 
       1. Neuropathy 
       2.Eye diseases 
              Retinopathy 
              Macular edema 
       3.Nephropathy 
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 MACROVASCULAR COMPLICATIONS 
1. Cerebrovascular  Disease 
2.Peripheral Arterial Disease 
3.Coronary Heart Disease 
OTHER COMPLICATIONS 
1.Hearing loss 
2.Periodontal disease 
3.Glaucoma  
4. Cataracts  
5.Infections  
6. Dermatological diseases  
7.Genitourinary 
                      Uropathy 
                      Sexual dysfunction 
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8. Gastrointestinal 
                       Diarrhea  
                       Gastroparesis  
Around 35 to 45 % of all diabetics are affected by microvascular 
complications. 
DCCT (Diabetes Control and Complications Trial) and UKPDS (United 
Kingdom Prospective Diabetes Study) have shown that progression of 
complications related to diabetes is prevented through good glycemic control. 
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ETIOPATHOGENESIS 
 
POLYOL-SORBITOL MECHANISM 
Aldose reductase is an enzyme that leads to accumulation  of sorbitol at the 
cellular level in various diabetic conditions. Various protective organic 
osmolytes levels are decreased in diabetics due to high intracellular sorbitol 
levels, they can lead to promotion of developing macro and micro vascular 
complications.  
           This mechanism was used in developing the drugs which inhibit aldose 
reductase, which causes reduction in intracellular sorbitol levels by restoring 
protective osmolytes levels. Signal transduction mediated in cellular functions 
are affected due to high sorbitol levels which then leads to reduction of 
protective osmolytes such as taurine and myoinositol. 
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MYOINOSITOL PATHWAY              
               Plasma and tissues in mammals contain cyclic hexitol known as 
Myoinositol. It is the most important content in cell membranes and 
phospholipids. Peripheral nerves contain high concentration of myoinositol. 
Glucose 6 phosphate synthesis and phosphoinositol hydrolysis causes 
maintenance of tissue myoinositol levels maintenance.  
             High intracellular glucose levels leads to myoinositol depletion in 
tissues, which leads to Na+K+ATPase inhibition. Myoinositol uptake is 
decreased in presence of low Na+K+ATPase.   
            Nerve fibre regeneration gets impaired in presence of low  myoinositol 
and correlates well with the clinical neuropathy responsible for  impaired and 
neurological damage seen in patients  with diabetes.  
            Metabolism of prostaglandins and synthesis of nitric oxide gets 
impaired in presence of deficiency in myoinositol. This leads to defective nitric 
oxide production and alteration in cyclo oxygenase pathways  leading to 
peripheral nerve defects causing complications.  
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Treatment with analogs of prostaglandin E 1 causes improvement in 
myoinositol levels, thereby leading to some kind of improvement in 
microvascular complications. 
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PERICYTES LOSS 
           Pericytes gets destroyed due to accumulation of sorbitol. Loss of 
pericytes leads to altered blood flow in retina, leading to tissue hypoxia  and 
capillary permeability gets increased. These changes lead to diminished 
synthesis of vasodilatory molecule nitric oxide. Low levels of nitric oxide  
leads to sympathetic tone augmentation, excess release of acetyl  choline and 
increase in angiotensin 2 production. 
          Protective intracellular osmolytes gets depleted because of low blood 
flow  due to diminished nitric oxide leading to complications of 
microvasculature. 
   
NITRIC OXIDE PATHWAY 
         Maintanence of sodium–potassium adenosine triphosphatase activity is 
mediated by nitric oxide, which is important for  transmission of impulses and 
metabolism of nerves. Many metabolic defects occur due to disruption in 
pathway of nitric oxide. 
               Aldose reductase inhibitors have benefit  of  preventing  most  of the 
microvascular problems  from  the disease and preserve nerve conduction 
velocity. Most patients gets their symptom relieved and microvascular 
complications progression gets halted due to use of aldose inhibitors.  
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              Many pathways  are involved in the pathogenesis of complications, 
aldose inhibitors alone provide only some benefit. 
 
ADVANCED GLYCATION END PRODUCTS ( AGE ) 
         AGE are formed due to lipoproteins or proteins glycation by sugar 
moieties. High blood glucose within the tissue causes production of AGE both 
in the intracellular and extracellular tissues. 
         Various modes of formation of AGE are:  
                     1. Glucose derived deoxy fructose lysine adducts decomposition 
causes formation of Amadori products 
                      2. Phosphate compounds fragmentation 
                      3. Glucose oxidation intracellularly 
            Glycosylated hemoglobin used to measure average blood sugar in 60 
days is an good example of AGE. Increased permeability of the basement 
membrane in the glomeruli of renal interstitium is due to advanced 
glycosylation. Microalbuminuria and macroalbuminuria result due to increase 
in capillary permeability. 
             Procoagulant and molecules of pro inflammation gets expressed due to 
AGE binding to its receptors. This leads the patient to high risk of infections 
and wound healing impairment. Formation of AGE enhances with increase in 
age and also in conditions like diabetes. 
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            In recent times many AGE inhibitors are identified. They act through 
various mechanisms that include : 
           1.Inhibition of periodontal inflammation 
         2.Inhibition of albuminuria 
         3.Increased nerve terminal conduction velocities 
          4.Increase in arterial elasticity                
 
REACTIVE OXYGEN SPECIES ( ROS ) 
              Various enzymatic and non enzymatic mechanisms due to oxidative 
stress from increased blood sugar causes formation of free radicals. Imbalance 
between Reactive oxygen species and endogenous cellular defense causes 
oxidative stress.  
              Presence of oxidative stress causes within endothelium inhibition of 
barrier function leading to adhesion of leukocytes and reduction in levels of 
nitric oxide. 
               These free radicals leads to activation of various signalling pathways 
which leads to oxidation of proteins, lipids, intracellular mitochondrial DNA 
causing tissue damage. Low nitric oxide due to free radicals causes adhesion of 
inflammatory cells to the endothelium. This results in impairment of 
endothelial barrier function leading to endothelial dysfunction and occurrence 
of microvascular complications.  
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                 .  
     PROTEIN KINASES  C ( PKC ) 
                 The Protein Kinase C (PKC) are  group of phospholipid-dependent 
protein kinases. These kinases  mediate various cellular responses to growth 
factors, hormones and the  neurotransmitters. They make an important part in 
vasodilatory substances release mechanisms and also in activation of 
endothelium.   
               PKC levels rise to massive levels due to persistent hyperglycaemic 
state. Since PKC is an substance of pro inflammation, it causes increased 
permeability of endothelium due to release of  Vascular Endothelial Growth 
Factor (VEGF). 
                    PKC also leads to increase in the production of Plasminogen 
Activator Inhibitor 1 (PAI 1) which leads to complications in the heart due to 
activation of Nicotinamide Adenine DiNucleotide Phosphate (NADPH)-
dependent oxidases.  
                    Based  on the patient’s genetic background, the prevention of 
impairment in angiogenesis in diabetic retinopathy due to the use of PKC 
inhibitors varies. 
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Signal transduction are mediated through  PKC-activated NF-κB (a nuclear 
transcription factor) which leads to proinflammatory effects.  
Various other growth factors which get transcripted by  protein kinase family 
include the following: 
 
1. Vascular Endothelial Growth Factor (VEGF ) , which causes increase in 
neovascularisation and permeability due to endothelium increases. 
2. A  potent vasoconstrictor, Endothelin 1. 
3.Promotion of expansion of matrix due to Transforming growth factor ( TGF )  
4. Vascular wall growth induction by the Platelet-derived growth factor-β         
( PDGF ) 
. 
 
 
 
 
 
 
 
 
27 
 
 
HEXOSAMINE PATHWAY 
                  Excess blood glucose present in the intracellular environment due 
to hyperglycaemic state causes this glucose to enter the hexosamine pathway. 
This leads to synthesis of many proteoglycans due to diversion of fructose 
phosphate from glycolytic pathway. 
                 Activation of hexosamine pathway leads to intracellular increase of 
hydrogen peroxide. This increased hydrogen peroxide causes dysfunction of 
beta cells due to insulin release impairment since hexosamine pathway is 
actively sensitised by beta cells present in the pancreas. 
                Hexosamine pathway activation also leads to high stress on beta cells 
in the pancreas which causes dysfunction of the beta cells as well as 
impairment of resistance to insulin.There are many studies regarding inhibitors 
of hexosamine pathways. The best results came from N- Acetyl Cysteine 
which is a potent anti oxidant. It causes decrease in the various changes 
occurred due to pathway of hexosamine. 
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OTHER MECHANISMS 
               1.Electron transport chain in mitochondria causes over production of 
superoxide anions. This leads to all major manifestations in the diabetes. 
Progression of retinopathy even with good glycemic control is due to the 
production of these superoxide anions. 
               2. Peroxisome proliferator-activated receptor ( PPAR ) activation 
inhibition due to mutations in the DNA of mitochondrium due to 
hyperglycemia. This leads to defective electron transport chain leading to 
production of superoxides causing damage to tissues. 
                3. NF-κB pathway aberrant regulation leading to arteriosclerosis and 
damage to tissues. This pathway causes dysregulation of various receptors like 
VEGF expression which leads to various derangements in the metabolism. 
                These other mechanisms causes tissue damage by different pathways 
leading to various complications seen in the patients with type 2 diabetes 
mellitus. 
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GLUCOSAMINE 
             Glucosamine leads to increased effect on Plasminogen Activator 
Inhibitor 1 (PAI 1). This effect leads to protein kinases c activation. Hence use 
of glucosamine in the diabetic individuals should be weighed against this 
potential risk. 
 
OTHER KINASE PATHWAYS 
                       The net reslts of various other kinases pathways activation 
include: 
1.Enhancement of  insulin resistance, 
 2.Related tissue damaging 
3.Worsening hyperglycemia   
                      These changes end in a continuum of increased insulin resistance 
due to deteriorating hyperglycemia. This causes activation of various cell 
damaging mechanisms.Few studies have proven that α-lipoic acid an 
antioxidant causes retardation in the progression of these destructive molecular 
pathways. This antioxidant also found to cause reduction in fructosamine 
levels in some patients with diabetes mellitus. 
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DIABETIC RETINOPATHY 
                     21% of patients were found to have diabetic retinopathy even at 
the time of diagnosis of diabetes.  Diabetes is one of the leading cause of 
blindness in individuals between the ages of 20 and 74 years. After 15 years of 
duration of diabetes, around 90% of patients were found to have retinopathy 
and.  
                   Retinopathy is causing upto 12,000 to 24,000 cases of blindness 
every year. Permanent retinal injury with ongoing  visual loss may have 
already occurred when the patient approaches the doctor with complaints of 
blurred vision. Therefore initial screening by the the  primary care physician is 
critical.  
                  Every part in human eye is susceptible to the detrimental effect of 
diabetes. Comparing to non diabetics, diabetic people have 25 times more 
chance of developing blindness. In India , DR ranks sixth common cause of 
blindness.  
                The relative risk is more in the age group of 30 to 60 years. It is 
unusual under children of 10 years of age. DR is usually present at the time of 
onset of symptoms in type 2 diabetes mellitus, whereas type 1 diabetes 
mellitus patients are free of DR during first 5 years of diagnosis. 
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                  The incidence of loss of vision increases with increasing age, 
severity of retinopathy, diabetes duration ,presence of proteinuria and high 
glycosylated haemoglobin levels.  
Blindness in a patient with retinopathy usually results from any one 
of the following causes: 
1.Non resolving vitreous hemorrhage 
2.Traction retinal detachment  
3.Diabetic macular edema.  
               However, the 5-year risk of severe visual loss can be 
greatly reduced to less than 2% if a person with diabetic retinopathy 
approaching or just when reaching high-risk proliferative 
retinopathy, as defined below, undergoes the procedure -Scatter 
(Panretinal) laser photocoagulation surgery. Intensive glycemic 
control causing delay in onset and slowing progression of 
retinopathy were clearly proven by DCCT and UKPDS trials.  
               Furthermore, people with CSME, Clinically Significant 
diabetic Macular Edema can decrease their risk of visual loss from 
50% to approximately 12% or less, if they undergo appropriate focal 
laser surgery.  
                Because diabetic retinopathy is most often asymptomatic 
in its most treatable stages, early detection and treatment of diabetic 
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retinopathy through regularly scheduled ocular examination is 
critical. 
                   Sudden loss of vision in a patient with retinopathy is usually the 
result of  any of the following: 
1. CNS stroke 
2. Onset of bilateral macular edema, which is associated with cardiac or renal 
failure or severe anemia. 
3. Retinal vascular occlusion 
4. Lens changes caused by fluctuating alterations in blood sugar 
5Vitreous hemorrhage  
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RISK FACTORS FOR DIABETIC RETINOPATHY 
 
1. DURATION OF DIABETES MELLITUS 
          The most important determining factor of retinopathy is duration. 
Around 50% of patients develop DR after 10 years of onset, 70% after 20 
years of onset and 90% after 30 years of onset of the diabetes. 
2. GENDER 
            Incidence is more in female population than in male population (4:3). 
3. METABOLIC CONTROL 
              Poor metabolic control correlates with the development and 
progression of  DR. 
 
4. HEREDITY  
             DR is transmitted as an Autosomal  recessive trait without sex linkage. 
This  effect is more on the proliferative type of  retinopathy ( PDR ). 
 
5. PREGNANCY 
                Moderate acceleration in the changes of diabetic retinopathy occurs 
in pregnancy. 
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6. HYPERTENSION 
 When patients have associated hypertension, it causes acceleration of the 
changes of diabetic retinopathy. 
7. OTHER RISK FACTORS 
             1. Alcohol  
             2. Hyperlipidemia 
             3. Smoking  
             4. Anemia 
             5. Obesity 
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PATHOGENESIS OF DIABETIC RETINOPATHY 
                   Diabetic retinopathy predominantly affects the veins, venules and 
venous end of capillaries. Basic pathophysiologic processes in the 
development of diabetic retinopathy include: 
 
(a) Pericytes loss associated with retinal capillaries  
 
(b)Basement membrane thickening 
 
(c) Changes in the blood flow in retina 
 
(d)Outpouching of capillary walls forming microaneurysms  
  
(e) Closure of retinal capillaries and arterioles resulting in retinal     
     nonperfusion 
  
(f) Increased vascular permeability of retinal capillaries  due to 
     breakdown in the Blood/Retinal barrier.  
  
(g) Proliferation of vessels in retina and iris  
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(h) Development of  the fibrovascular tissue 
 
(i) Fibrous proliferation and contraction of vitreous causes vitreous 
     hemorrhage and retinal detachment due to traction. 
 
HEMORRHAGES AND/OR MICROANEURYSMS 
                 The various diabetic retinal lesions and along with their 
severity, both alone and in aggregate, are the exact predictors of the 
diabetic  retinopathy progression and ensuing visual loss. Various 
lesions in diabetic retinopathy is because of various pathologic 
processes and interactions during the diabetes course and 
development of diabetic eye disease.  
                 The retinal pericytes, which are intimately associated 
within the basement membrane of the endothelial cells in retina, a re 
normally present in a one-to-one ratio with the endothelial cells. This 
is a ratio higher than found anywhere else in the body. This finding 
and other cell-culture data have strongly  suggested that the retinal 
pericytes were critical supporting cells for the retinal capillaries.  
                  The loss of this  retinal pericytes is thought, therefore, to 
be a factor contributing for the development of endothelial cell 
dysfunction and weakness within the  retinal capillary wall, possibly 
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contributing to the formation of the  microaneurysms, which, along 
with venous dilatation, producing  early clinicals.  
                    Micro-aneurysms, which occur due to retinal capillaries  
saccular outpouchings  are  the early clinical signs of patients with 
diabetic retinopathy. Intraretinal haemorrhages are common due to 
IRMA, IntraRetinal Microvascular Abnormalities .  
                    These hemorrhages reflect  the retinal level of the 
hemorrhage and retinal architecture due to the ruptured 
microaneurysms and leaking capillaries. 
                  Since the structure of the nerve-fibre layer runs exactly 
parallel to the retinal surface, it gives it a flame-shaped appearance. 
The more characteristic lesions of diabetic retinopathy are the 
pinpoint or dot shaped haemorrhages which occur in the deeper 
retinal layers. Here the arrangement of cells is perpendicular to the 
surface of the retina and gives itsclassical appearance.   
                  The term “dot/blot hemorrhages” were used to describe 
these small intraretinal hemorrhages which were characteristic of 
diabetic retinopathy. Because it is very difficult, if not impossible, to 
distinguish these small dot/blot hemorrhages from that of  
microaneurysms, and because critical evaluation of these two  lesions 
has determined that there is little additional clinically significant 
information is obtained by differentiating  two lesions, they are 
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classically evaluated together and referred  as “hemorrhages and 
microaneurysms.” 
 
VENOUS CALIBER ABNORMALITIES 
                    Venous caliber abnormalities are now found to be the early 
indicators of possible diabetic retinopathy. It is an indicator of severe state of  
hypoxia in retina. They can be loop formation, beading, venous dilatation. 
These venous changes occur usually where there are  areas of loss of perfusion 
nearby  to the veins. Treatment by scatter (panretinal) photocoagulation may 
cause these kind abnormal veins to become more normal in appearance over 
time. 
INTRARETINAL MICROVASCULAR ABNORMALITIES 
                    Through areas of nonperfusion, there is proliferation of 
endothelial cell that act as “shunts”. These pre existing vessels that some 
consider new vessel growth occur within the retina and are called Intraretinal 
microvascular abnormalities (IRMAs). 
                 IRMAs are seen in severe stages of Non Proliferative Diabetic  
Retinopathy ( NPDR ). It is a sign that neovascularization is about to appear on 
retinal surface  or on the optic disc within a short time. They are seen adjacent 
to cotton-wool spots. They are nothing but micro infarcts in the nerve- fibre 
layer of the retina.  
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RETINAL NEOVASCULARIZATION 
                  Proliferative Diabetic Retinopathy (PDR) is marked by the 
abnormal development of new vessels in the retina.. Neovascularization occur 
either at or near the optic disc [neovascularization of the disc (NVD)] or any 
other area on the retinal surface [neovascularization elsewhere (NVE)]. 
Fibrous tissue are found along with the new vessels which appear opaque. 
Later they become adherent to the nearby vitreous. There is variable rate of 
growth of these new vessels.  
                High-risk PDR patients are treated with scatter laser 
photocoagulation. High-risk PDR is diagnosed by any of the following lesions:  
 
(a) If fresh vitreous or pre retinal hemorrhage is present, size of NVE greater 
than or equal to one half of the disc area; or  
(b) Size of NVD approximately one fourth to one third of the  disc area or 
more in size; or 
(c) Size of NVD less than one fourth the disc area with fresh preretinal   or 
vitreous hemorrhage; 
                Because identification of these  high-risk characteristics is critical for 
determining the delivery of sight-saving care, the presence or absence of the 
preretinal or vitreous hemorrhage, the location of new vessels, the presence or 
absence of new vessels and the severity of the new vessels must be noted 
carefully.  
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LEVELS OF DIABETIC RETINOPATHY:              
 Scatter (panretinal) laser photocoagulation surgery should be considered 
in an individual with high-risk stage of  Proliferative diabetic retinopathy eye. 
The high-risk stage  is suspected when there are signs of severe or very severe 
NPDR or new vessels which are not satisfying the definition of high-risk PDR 
( Proliferative Diabetic Retinopathy), especially if it coexists with stage of very 
severe NPDR.  
When changes in two eyes are  unequal, changes in the eye with more 
severe involvement is taken for classification.  
 
 
  
 
 
 
 
 
 
 The following is the clinical classification of diabetic retinopathy :  
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 LEVELS OF RETINOPATHY 
NON  PROLIFERATIVE DIABETIC RETINOPATHY 
A. Mild NPDR 
  Presence of at least one  significant microaneurysm 
  Not meeting criteria for B, C, D, E, or F  
B. Moderate NPDR 
  Presence of IRMA or H/Ma is greater than standard photograph 2A  
or  SE, VB.  
  Not meeting the criteria for C, D, E, or F  
C. Severe NPDR 
  In at least one quadrant IRMA is greater than standard photograph 
8A   
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  VB in two or more quadrants or H/Ma greater than standard 
photograph 2A  in all four quadrants 
D. Very severe NPDR 
  Any two or more of C  
  Not meeting criteria for E or F 
PROLIFERATIVE  DIABETIC RETINOPATHY (PDR) 
At least one of the following, Composition of PDR  
  Fibrous tissue proliferation   
  NVD or NVE 
  Preretinal or vitreous hemorrhage 
E. Early PDR 
  Presence of New vessels 
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  Not meeting criteria for F 
F. High-risk PDR 
  NVE ≥ ½ disc area and preretinal or vitreous hemorrhage or 
  NVD ≥¼–1/3 disc area or  
  NVD and vitreous or preretinal hemorrhage 
CLINICALLY SIGNIFICANT DIABETIC MACULAR EDEMA 
  HE located ≤500 µm from the centre of the macula with adjacent 
retinal  thickening  or  
  A zone of retinal thickening, of size one disc area or larger, with 
any portion located ≤1 disc diameter from the centre of the macula 
or 
  Retinal thickening located ≤500 µm from the centre of the macula  
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NONPROLIFERATIVE DIABETIC RETINOPATHY 
                      NPDR also known as BACKGROUND RETINOPATHY is 
broadly divided into NPDR and PDR. Macular edema of diabetes can occur 
with either NPDR or PDR. Accurate diagnosis of the “diabetic retinopathy 
level” is crucial. The ongoing risk of progression to PDR and high-risk PDR 
varies according to it and is closely correlated with the specific level of NPDR 
in a patient. 
                        Microaneurysms were the early evidence for DR in around 25% 
of the patients. They are visualised as “red dots” in the posterior fundus. 
 
Hemorrhages- Flame shaped when appear in superficial nerve fibre layer; 
Blot shaped when appear in deeper layers. 
 
Soft exudates- Also known as cotton wool spots. They represent infarcts in 
nerve fibre layer. They are sign of capillary non perfusion. 
 
Hard exudates- white or yellow in colour. More common in elderly, increase 
in frequency with increasing duration of diabetes. They consist of lipoproteins.  
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Mild NPDR is marked by at least one retinal microaneurysm, but hemorrhages 
and microaneurysms are less in frequency than those in ETDRS standard 
photograph 2A  in all four retinal quadrants. No other retinal lesions or 
abnormalities associated with diabetes were present.  
 
 
Patients with mild NPDR on diagnosis have 5 percent risk of progressing to 
PDR within 1 year and a 15 percent risk of progressing to high-risk PDR 
within 5 years.  
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Figure 1  shows  Mild Non Proliferative Diabetic Retinopathy 
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               Moderate NPDR  is diagnosed by microaneurysms and/or 
hemorrhages  greater than those seen in ETDRS photograph 2A in at least one 
quadrant but in less than in four retinal quadrants, with or without evidence of  
venous beading and IRMA to a mild degree. The risk PDR to progress within 1 
year is 12% to 27% and the amount of risk to progress to high-risk PDR is is 
33% for 5 years . 
            Panretinal  laser surgery is not preferred for patients with mild or 
moderate NPDR. They can be followed up at 6- to 12-month intervals. The 
presence of macular edema, even with mild or moderate degree of NPDR, 
requires follow-up in a shorter period of time.  
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Figure 2 : Moderate Non Proliferative Diabetic Retinopathy 
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            Severe NPDR is based on the severity of H/Ma, IRMA, 
and/or venous beading and was determined by any one of the 
following lesions :  
 (a) In at least one  quadrant,IRMA greater than in ETDRS standard 
      photo 8A or 
 (b) In four   quadrants, H/Ma greater than in ETDRS standard photo 
      2A or   
 (c) Two or more quadrants has venous beading   
               In 1 year, patients with severe NPDR have 52% risk of 
developing PDR. In 5 years there is 60% risk of developing high-risk 
PDR. These patients require follow-up in 2- to 4-month intervals. 
The clinical effectiveness of the  laser photocoagulation for the  
CSME along with PDR may be greatly reduced compared with 
treatment of CSME alone.  
                Treatment of clinically significant macular edema in 
patients with severe or very severe stage of  NPDR is strongly  
indicated because of a high risk of developing PDR and requiring 
scatter (panretinal) laser surgery in a relatively short span of  time.  
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In addition, scatter (panretinal) laser surgery can worsen macular edema is the 
another reason for optimizing the macular edema status of these patients who 
were likely to require scatter (panretinal) laser photocoagulation in the near 
term. 
 
4-2-1 Rule : Presence any one of the following indicates severe diabetic 
retinopathy: 
 Microaneurysms          - 4 quadrants 
 Venous beading           - 2 quadrants 
 IRMA                           - 1 quadrant  
 
              Patients with very severe NPDR  have lesions of that of  severe NPDR 
but there is no frank neovascularization. Within 1 year, these patients have 70-
75% risk of PDR. Patients with severe or very severe NPDR are the ideal 
candidates for scatter (panretinal) laser surgery, particularly those with type 2 
diabetes, and the  presence of macular edema, if present, often requires 
treatment. Frequent reevaluation at 2- to 3-month intervals is very important 
for these kind of  eyes. 
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Figure 3 shows  Severe Non Proliferative Diabetic Retinopathy 
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Figure 4 : Very Severe Non Proliferative Diabetic Retinopathy 
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PROLIFERATIVE DIABETIC RETINOPATHY 
                        Diabetic retinopathy, characterised by neovascularisation on the 
optic disc (NVD) or elsewhere in the retina (NVE) or by the  fibrous tissue  
proliferation is designated as PDR. Early PDR need not fulfil the definition for 
high-risk PDR . Eyes with early changes of PDR  (less than high risk) have a 
75 percent risk of development of  high-risk PDR in a course of period of five 
years. 
                       These eyes may require the  scatter (panretinal) laser surgery. 
Macular edema, even if not  significant clinically, may benefit from the  focal 
treatment before scatter is initiated, as discussed previously (nonproliferative 
diabetic retinopathy). 
                 In patients with early PDR changes (less than high-risk PDR), early 
scatter (panretinal) laser surgery must be considered if any of the associated 
findings are present 
(a) any new vessels accompanied with  severe or very severe NPDR, 
(b) elevated new vessels,  
(c) or NVD.  
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                In  patients with severe NPDR changes, if macular edema is present,   
focal treatment of macular edema  is done even if the macular edema is  not 
clinicallyimportant, as an initial preparation for the use of scatter laser 
photocoagulation in future. 
                In severe or very severe NPDR or early PDR, the type of diabetes is 
very  important. It has been demonstrated by the ETDRS that in type 2 
diabetes patints risk of severe visual loss is more. Hence vitrectomy surgery 
can be avoided to almost  50% if scatter (panretinal) laser surgery is initiated 
before the onset of high-risk PDR.  
              In contrast, type 1 diabetes patients showed not much advantage in the 
risk of loss of vision or for vitrectomy even if laser surgery is delayed until the 
development of PDR with high-risk characteristics. 
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Figure 5 : Proliferative Diabetic Retinopathy 
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Figure 6 : Clinically Significant Macular Edema 
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DIABETIC MACULAR EDEMA 
                     Diabetic macular edema can be associated with any stage of 
retinopathy .  
Alterations in the macular structure  observed in diabetes  include : 
(a) Fibrous-tissue proliferation causes dragging of  retinal tissue, surface 
 wrinkling, detachment of the macula producing traction in the macula  
(b) Parafoveal capillaries nonperfusion with or without intraretinal 
 fluid   
     (c) Full-thickness or lamellar hole formation in retina 
     (d) Preretinal or intraretinal hemorrhages in the macula 
      (e) Intraretinal fluid collection in the macula with or without  lipid exudates 
         with or without the cystoid changes and intraretinal fluid collection in the  
         macula   
      (f) Multiple combinations of the above. 
                       Macular edema is   defined as retinal thickening within two disc 
diameters in the centre of the macula. This definition is not based on the 
presence of  the fluorescein leakage. Hard exudates with adjacent retinal 
thickening threatening or involving the centre of the macula is clinically 
important. 
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CSME elaborated by the ETDRS has any one of the following lesions as 
mentioned:  
 
(a) Retinal thickening of at least one disc area in size, part of it is within one 
disc diameter within the centre of the macula. 
 (b) Thickening of retina in or within   500 µm from the centre of the macula  
 (c) Adjacent retinal thickening with hard exudates at or within the  500 µm 
        from the centre of the macula  
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Figure 7 : Clinically Significant Macular Edema 
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ROLE OF CLINICAL FLUORESCEIN ANGIOGRAPHY IN 
MANAGEMENT OF RETINOPATHY: 
                         In the presence of CSME it is valuable to detect potentially  
treatable lesions by doing Fluorescein angiography to the macula. However, its 
not used to identifying lesion like NVE or feeder vessels as it is usually 
unnecessary because the lesions are clinically evident and scatter (panretinal) 
laser surgery is the treatment method of choice for  of diabetic retinopathy as it 
approaches or reaches the stage of  high-risk. 
                      Certain  risk factors for the  progression of NPDR to full blown 
PDR have been identified in angiography. Analysis of the data for the 
untreated (deferred) eyes in the ETDRS indicates that the following lesions 
were independently related to outcome:  
 
(a) leakage of the fluorescein,  
(b) capillary loss on the  fluorescein angiography,  
(c) capillary dilatation on the fluorescein angiography, and  
(d) the following color fundus photographic risk factors: IRMA, venous 
beading, and H/Ma.  
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            Hard and soft exudates have an inverse relationship to the  progression 
of diabetic retinopathy. It is widely accepted that capillary loss as documented 
in the fluorescein angiography is a risk factor for progression from NPDR to 
PDR .  
            However, capillary dilatation on the fluorescein angiography, 
fluorescein leakage capillary loss on the  fluorescein angiography, and the 
ETDRS color fundus photographic retinopathy are all very  closely correlated.  
              Color fundus photography used in grading of retinopathy levels of the 
eyes also give prognostic results . Therefore, it is not of significant clinical 
importance to warrant routine use of  fluorescein angiography to predict 
disease progression. 
              Follow-up retinal examinations, however, are very important. The 
appropriate interval can be determined by the  skillful grading of seven 
standard-field stereo color fundus photographs and/or retinal evaluation by the  
experienced examiner.  
                The stage of diabetic retinopathy  derived from the  color fundus 
photography or retinal ophthalmic evaluation is very closely correlated with 
the rate of diabetic retinopathy progression, the accurate determination of  
retinopathy level  becomes  paramount clinical importance and it  determines 
the appropriate retinal reevaluation interval.  
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Fluorescein angiography cannot “identify all cases destined to progress”. 
Periodic follow-up of all patients with diabetic retinopathy continues to be of 
fundamental clinical importance because scatter (panretinal) laser 
photocoagulation should be doneas diabetic retinopathy nears the high-risk 
stage . 
 
 
LASER PHOTOCOAGULATION 
Timing of Photocoagulation 
                    In the ETDRS, the risk from moderate visual loss due to  macular 
edema without any  treatment with focal laser was around 30 percent. Focal 
laser surgery for CSME reduces this risk to 15% or less , a reduction in risk of 
approximately around 50%, and focal treatment also increases the chance of 
improvement in the visual acuity of one line or more.  
                   On the other hand, scatter (panretinal) laser surgery was not as 
effective in managing diabetic macular edema and in few cases may have had 
a deleterious effect on the progression of macular edema. 
                  Eyes with CSME and retinopathy approaching to high-risk PDR  
are best treated initially  with focal photocoagulation for the macular edema  
for about  6 to 8 weeks before initiating scatter (panretinal) laser surgery.   
Eyes with mild to moderate NPDR and CSME respond well to prompt focal 
photocoagulation, with scatter treatment delayed.                                  
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                          Delaying scatter photocoagulation during  focal treatment is 
being completed is unlikely to worsen the risk of visual loss, provided the 
retinopathy is not progressing very  rapidly and regular follow-up can well be  
pursued. Late scatter photocoagulation while  the focal treatment is completed 
in eyes with high-risk PDR usually is not advised, and the macular edema will 
usually be treated in  the first treatment session of scatter photocoagulation. 
                        
                         Focal treatment was not attended by the adverse effects on 
central visual field or color vision in comparison with the  eyes assigned to 
deferral of focal treatment in the ETDRS. Any harmful effects due to  early 
photocoagulation as reflected by constriction of the peripheral visual fields 
seem to be due mostly to the  scatter photocoagulation.  
                        Because the principal benefit of the treatment is the prevention 
from further decrease in the visual acuity, focal laser surgery should be 
considered in all eyes with the level of  CSME, especially if the macula is 
threatened, even with normal vision. 
 
 However, it should be noted that macular edema that is not particularly 
extensive may spontaneously resolve in as many as 30% of patients. Thus, in 
cases where visual acuity is excellent, the fovea is not particularly threatened 
due to edema, hard exudates, or subretinal fibrosis, the likelihood for 
requirement of  scatter (panretinal) photocoagulation in the near future is very  
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low, and the patient demonstrates excellent compliance with the follow-up 
evaluations, the edema may, at the discretion of the patient and the treating 
physician, should be monitored carefully without the  immediate focal 
photocoagulation.    
 
 
 
 
 
Figure 8 : Focal Photocoagulation 
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 However, should the visual acuity show the signs of deterioration, the macular 
edema show signs of progression, or the retinopathy level advance to a stage 
where panretinal scatter laser photocoagulation is most likely in the near 
future, prompt focal laser surgery for the macular edema is usually  indicated. 
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Figure 9 : Pan retinal Photocoagulation 
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                  The DRS showed in 1976 that pan retinal scatter photocoagulation 
was very effective in reducing the risk of severe visual loss due to high-risk 
PDR. The DRS did not provide a clear guidance between the  treatment or 
deferral of the treatment unless there was high-risk PDR.  
                    So one question of concern of the ETDRS is whether to go for 
earlier laser photocoagulation, before the progress to high-risk PDR, justified 
the side effects and risks of  the laser surgery. 
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Side Effects and Complication of Scatter Laser 
Photocoagulation 
Side effects 
  Changes in color vision  
   Internal ophthalmoplegia 
  Constriction of peripheral field  
 Night blindness   (Nyctalopia) 
Complications 
 Tractional retinal detachment  due to progression of retinopathy   
 Rhegmatogenous retinal detachment and secondary retinal hole  
Burn in fovea 
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   Macular edema  
 Traction of fovea 
  Lens and  corneal burns 
Retrobulbar anesthesia injection which is rarely used now 
causes    retrobulbar  hemorrhage 
   Acute angle–closure glaucoma 
 Choroidal or serous detachment 
 
 
                  In the ETDRS, during  early treatment, compared with deferral of 
photocoagulation therapy until signs of PDR appears, was associated with  a 
insignificant lowering in the incidence of impairment of vision; however, the 
5-year rates were similar for both the early-treated group and the group which 
is assigned to “deferral” of treatment (2.6% and 3.7%, respectively).                      
                If careful follow-up is done, scatter laser surgery is not usually 
recommended for mild or moderate NPDR. For severe or very severe NPDR 
and early PDR, scatter photocoagulation should definitely be done and usually 
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should not be delayed if the eye has reached to the high-risk proliferative 
stage”. When the high-risk stage is reached the benefits and the risks of early 
photocoagulation may be roughly balanced and weighed.  
                            Initiating scatter photocoagulation early in at least one of the 
eye seems particularly appropriate when both of the patient's eyes are 
approaching to the high-risk stage, as optimal timing of photocoagulation may 
be very  difficult if both eyes require photocoagulation simultaneously. Also, 
prompt scatter photocoagulation of the retina should be considered when new 
vessel formation takes place in the angle of anterior chamber irrespective of 
high-risk PDR.  
                         It has been demonstrated in the ETDRS that patients diabetes 
have decreased risk from severe loss of vision or vitrectomy by around  50% if 
scatter (panretinal) laser surgery is initiated early. In contrast, patients with 
type 1 diabetes showed not much  difference, even though visual loss or the  
laser surgery was delayed until later stage. 
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Treatment Program 
                      The treatment program  for diabetic retinopathy consists of  
(a)Initial scatter laser photocoagulation procedure 
  (b) careful follow-up regularly at 3- to 4-month intervals following the   
       treatment  
(c) re-treatment of recurrent treatable or persistent  lesions  
(d)  Use of focal laser photocoagulation for the  macular edema prior to scatter 
(panretinal) photocoagulation method  to reduce the risk of progression of 
macular edema that is  secondary to scatter photocoagulation. 
                             
 
                 As high-risk PDR stage is reached, the major threat for severe visual 
loss is traction retinal detachment. A lesser threat is persistent  loss of vision, 
but a more common complication, is vitreous hemorrhage. The primary goal of  
scatter laser surgery is that  the prevention of traction retinal detachment, 
particularly that  involving the macula. 
                          
                    Various strategies are involved in the treatment   follow-up. The 
ocular lesions which are to be considered for follow-up photocoagulation 
include new neovascularization which is flat or elevated neovascularization 
and new, persistent, or recurrent CSME.  
72 
 
 
                    The treatment methods include additional scatter laser treatment, 
local laser treatment  to NVE, focal laser theraphy  for CSME, pars 
plana vitrectomy for recurrent hemorrhages with fibrovascular proliferation 
leading to traction and  when appropriate, continued observation. Furthermore  
scatter treatment may be placed in between previously placed laser scars as 
long as these kind of scars do not become confluent and the extent of the 
scatter treatment is not such as to totally destroy the  retinal function.                      
                      Although laser surgery often considered to be painless, some 
patients may experience discomfort in association with the treatment 
procedure. There usually is some discomfort or pain for all patients when the 
peripheral retina is treated.  
                     In summary, the risk of severe visual loss from PDR is reduced 
by scatter laser treatment. Both early scatter treatment prior to the development 
of high-risk PDR and deferral of the  treatment until later reduces significantly 
the risk of visual loss. The mean rates of visual loss are same for each group 
after the treatment.  
                   Consequently, it is concluded that the laser treatment need not be 
used for mild and moderate NPDR. For severe NPDR and early PDR stages, 
scatter treatment is ideally appropriate when close follow-up of these patients 
is unlikely, the disease process is progressing very rapidly, or in type 2 
diabetes patients. 
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FUTURE HORIZONS 
 
Molecular /Cellular Advances 
                     In the past several decades, remarkable advances in the  
understanding of the basic mechanisms underlying the diabetes and diabetic 
retinopathy have been achieved.  
                     These new insights into the processes which underly the 
fundamental molecular and cellular changes ultimately leading  to sight-
threatening complications of diabetic retinopathy are permitting to the 
development of new interventional approaches. These newer  therapeutic 
modalities hold great promise for the further reduction or elimination of the 
complications of diabetic eye disease. 
                       
                        Advances have been made in understanding many of the areas, 
including the changes which underlying in the sorbitol pathway, the 
development of the oxidative stress, protein kinase C  activation and the 
formation  of the advanced glycosylation end-products.  Each of these various 
pathways has been associated with  variety of the complications of diabetes, 
and they are often intimately related to each other. 
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                         An area of substantial study has been in the increased flux 
through the sorbitol pathway in those cells exposed to a hyperglycemic 
environment. Consequently, aldose reductase inhibitors have been extensively 
evaluated for their potential use in ameliorating the diabetic retinopathy. A 
multicenter clinical trial, tested whether the  daily dose of sorbinil could reduce 
the complications of diabetes mellitus.  
                      
                      Over a 3-year period, the drug had found to have no effects on 
the type 1 diabetes of moderate duration . However, the group which were 
taking sorbinil did show a slight lowering in the  microaneurysms number. 
Unfortunately, there were complications in nearly 5-7% of the initial 
participants taking the drug.  
                      These adverse reactions in the skin  included are toxic epidermal 
necrolysis, erythema multiforme, and Stevens-Johnson syndrome. Because of 
the lack of efficacy in humans and the associated major side effects, no aldose 
reductase inhibitors were currently being used on a routine clinical basis for 
diabetic retinopathy treatment. 
                   
                        A variety of studies has also looked at the  antioxidants as a 
potential ameliorator of the oxidative stress present under the diabetic 
conditions. Preliminary data on the antioxidants such as vitamin E have been 
promising with regard to prevention or reversal of  early changes in retinal 
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circulation  and in correcting the abnormal retinal blood flow present in 
patients with history of  short-duration of  diabetes and minimal diabetic 
retinopathy . 
                     
                          When proteins were exposed to high levels of the glucose for 
extended period of time, AGEs may be formed. Recent studies have suggested 
that the formation of these AGEs can cause a variety of changes in the cellular 
processes and may contribute to diabetic ocular complications. Inhibitors of 
AGEs are being in evaluation  for clinical usefulness. 
                      Newer modalities of treatment include PKC inhibitors. 
Activation of this protein kinase C enzyme can result in wide-ranging effects 
underlying endothelial dysfunction in  eyes and other organs. In addition, 
protein kinase C is the key mediator of signaling processes induced by other 
growth factors involved in the  retinal neovascularization, diabetic macular 
edema, and perhaps also in the earlier stages of diabetic retinopathy as well.  
                      
                     A particular isoform (the β isoform) of protein kinase C appears  
specifically to  mediate many of the complications arising in the eyes. 
Consequently, inhibitors of the  protein kinase C β have been evaluated in 
detail, with documented ability to normalize the retinal blood flow, 
suppression of  retinal permeability, prevention of  retinal neovascularization, 
76 
 
and normalization of  retinal blood flow in patients with no or mild 
nonproliferative retinopathy.  
               These agents are currently in the clinical trials to determine whether 
they can prevent or cause slowing of  the progression of diabetic retinopathy 
and/or diabetic macular edema. Results from these studies are expected in the 
forthcoming few years. 
                     Another promising area in the  investigations is the evaluation of 
the various growth factors which mediate the later-stage complications of 
diabetic retinopathy. Numerous angiogenic agents, such as vascular endothelial 
growth factor, which have been identified as the  key modulators of the retinal 
neovascular response and the increase in the retinal vascular permeability.  
                      Several inhibitors of these agents have been developed with very 
promising results observed over time and in the next few years may add 
significantly to the therapeutic armamentarium.  
                     In addition, preliminary results from some small uncontrolled 
studies suggest that intravitreal administration of the  steroids may have a 
significant effect in reduction of the  diabetic macular edema and may actually 
cause  improvement in vision in a subset of these patients. Currently, a number 
of these agents were in clinical trials. 
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PREGNANCY AND DR 
                       Women with diabetes mellitus who are above to get  pregnant 
should  undergo a detailed eye examination before they conceive. In each 
trimester of their pregnancy diabetic pregnant women should ideally have  
eyes examination very early or often more frequently, as indicated by the  
levels of retinopathy, and usually 6 weeks after delivery.  
                       Pregnant women can have worsening of retinopathy, as well as 
they may also have coexistent systemic hypertension, they should be 
monitored carefully throughout the course of pregnancy. 
                      In women with PDR, in some cases cesarean delivery may be 
considered rather than vaginal delivery to reduce the risk of vitreous 
hemorrhage. A team work is needed between various faculties of  medical 
team for caring of  pregnant  diabetic individual . 
                      Various treatment modalities available such as laser 
photocoagulation should be discussed in detail with the patients even with the 
milder forms of retinopathy for diminising the visual loss. Furthermore, 
patients with the visual impairment of any degree, legal blindness, or total 
blindness should be informed about the availability of visual, vocational, and 
psychosocial rehabilitation programs. 
                   During early stages of DR, symptoms are not much prominent in 
the individuals. Vision  may be very good at the time of initial diagnosis of 
diabetic retinopathy, even when significant ocular disease is present. 
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Educational program at regular intervals  and medical and ocular follow-up 
should be instituted at the very early stages itself. 
                        
                     As the retinal disease progresses, visual acuity may become 
compromised by the macular edema, episodes due to  hemorrhage in the 
vitreous, macular non perfusion, or traction retinal detachment. Significant 
difficulties in the work or in the home environment can be caused due to such 
kind of loss of vision. This loss very often puts extreme psychologic stress on 
patients with the diabetes and their families. The healthcare provider should 
identify some stress factors , and appropriate support for the patients should be 
offered in the early stage of the disease itself.  
                          
                     In many cases, the patient will experience a significant drop in the 
visual acuity for a period of time. Although in many cases excellent vision can 
be ultimately  obtained and retained over  many decades, the period during 
which the diabetes  patient experiences this kind of  visual decline can lead to 
great uncertainty and anxiety. 
                       
                         It is of critical importance that the level of ocular disease 
should be monitored carefully and appropriate observation, laser treatment, 
vitreoretinal surgery, or other interventional procedures to be applied promptly 
whenever  indicated. If these approaches are strictly followed, most patients 
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can very well  retain excellent vision over  many decades of stable ocular 
status once the diabetic retinopathy has become quiescent. New therapies on 
the horizon promise even more better outcomes. 
                     
                       Thus, it is obvious that a very close interaction between the 
diabetes patient and a diverse healthcare team is essential. The healthcare team 
will commonly require services from  both the ophthalmologist and internist, 
as well as from the diabetologist, nursing  practitioner, diabetes educator, 
dietician, psychosocial worker, and very many other specialties, depending on 
the particular situation.  
                    
                       With such access, carefully monitored and well planned   routine 
ophthalmic follow-up, optimization of the glycemic and systemic medical 
control, and timely initiation of laser photocoagulation, the risk of blindness in 
persons with the  diabetes mellitus can essentially be eliminated. 
                       
Fetal loss is more in presence of diabetic retinopathy and the rate increases 
with increasing severity of the retinopathy. The explanation is that the 
retinopathy is often associated with angiopathy elsewhere and poor placental 
blood perfusion because of microangiopathy may be the cause of high fetal 
loss. While the mere presence of diabetic retinopathy in a pregnant women is 
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not an indication for termination of pregnancy, it may become necessary if the 
retinopathy shows progression. 
                    Though there is a extreme view that diabetic women with 
retinopathy should be advised not to conceive, there are no enough evidence to 
support this concept. Malignant retinopathy certainly worsens rapidly during 
pregnancy, but the exact reason behind this is not known. In a proportion of 
patients after delivery, diabetic retinopathy shows regression.   
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HYPERTENSION AND DIABETIC 
RETINOPATHY 
                           Patients with higher  blood pressure were more likely to 
develop diabetic retinopathy. The UK Prospective Diabetes Study (UKPDS) 
also found the higher relative risk for incidence of retinopathy with higher 
systolic blood pressure in an individual.  
                 Hypertension causes hyperperfusion and auto regulation impairment 
which causes changes in hemodynamics and leads to the development of DR. 
In addition, formation of diabetic retinopathy due to hypertension is by  
increased expression of vascular endothelial growth factor in the endothelial 
cells of retina and ocular fluids, leading to new vessels formation. 
                 Presence of both systolic as well as diastolic hypertension can lead 
to the progression of DR. 
                         In the  UKPDS trial,  it was proven that there occurs major 
reduction in complications due to micro vasculature by very good control of 
systemic hypertension. 
                       Presence of hypertension leads to the formation of DR by 
several mechanisms.These include the following: 
1.Proliferation of small and new vessels due to increased expression of 
vascular endothelial growth factor. 
2.Damage and destruction of  endothelium of retina. 
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3.Impairment of autoregulation of  vasculature in retina. 
 
                    With the occurrence of  microalbuminuria, blood pressure begins 
to rise. Once  macroalbuminuria  sets in, 60 to 70 % of the patients will 
develop hypertension. In the stage of renal failure most of the patients will 
have systemic hypertension. There are very well proven evidences that 
hypertension causing acceleration of microangiopathic  complications 
particularly the retinopathic complications. 
                   In a large randomised studies, average mean systolic blood 
pressure was found to be 10 to 12 mm higher in diabetic subjects when 
compare to the general population. Prevalence of systemic hypertension in 
type 2 diabetes mellitus is twice as that of  non  diabetic population. Subjects 
with hypertension have more hyperglycemia than those with normal BP and 
hypertensive patients are more susceptible to develop DM. Hence in a patient 
with DM and HT achieving  normotension is as important as achieving 
euglycemia. 
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ANEMIA AND DIABETIC RETINOPATHY 
                        Anemia is suggested as another long term complication of DM 
and defined as hemoglobin level less than 13 g/dl in men and 12g/dl in women. 
The prevalence of anemia in diabetes  mellitus individual  is reported as 
around  14-48% . In diabetes mellitus  patients, anemia is associated 
independently with the development of diabetic retinopathy, chronic kidney 
disease and cardiovascular illnesses like heart failure. 
                       In type 2 diabetes, anemia is the second cause leading to diabetic 
retinopathy next to hypperglycemia. Recent studies found that patients with 
low haemoglobin are in high risk to develop retinopathy changes. Anemia is 
also frequently seen in renal disease individuals.                      
                       It was found that in individuals with low haemoglobin, there are 
high  chances for retinopathy and significant loss of vsion. Patients were also 
at high risk for developing macular edema due to anemia. Treatment of anemia 
causes resolution of macular edema in few individuals.                     
                     The causes of anemia in an diabetes individual with mellitus are  
multifactorial. They are : 
 1. Decreased synthesis of erythropoietin.  
2.Chronic hyperglycemia is involved in the pathogenesis of anemia by means 
of creating abnormalities in RBCs, oxidative stress, autonomic neuropathy and 
renal sympathetic denervation. These conditions put the renal interstitium in a 
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hypoxic state and consequently, the production of erythropoietin by peri 
tubular fibroblasts is impaired .  
3.The other possible causes of anemia include functional erythropoietin 
deficiency, diabetic nephropathy, chronic inflammation, high levels of ultimate 
glycosylated  products, iron deficiency, anti- DM drugs and low testosterone 
levels as suggested by others .  
                        Regarding the effect of anemia on diabetic retinopathy , it 
seems that  the anemia-induced hypoxia leads to the increased release of 
vasoproliferative factors (X factor) and bring about the progression of  to 
severe form of retinopathy .  
                       Preceeding studies reported that the flexibility of  RBCs in DM 
patients is much less compared to normal individuals and this may be the 
reason for deterioration of complications of DM . 
                        DR due to anemia develops in an individual with duration of 
diabetes more than five years. From the above mentioned observations, it is 
better  to evaluate of anemia at an early stage and  should be considered in all 
individuals with DR. 
                        Anemia identification and  and its treatment is important in the 
management of DR. In few  patients who had both anemia (Hb-8g/dl) and DM, 
Friedman and associates found  that treatment of anemia  was correlated with 
very good resolution of macular hard exudates.  
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The increase in haemoglobin concentration causes diminished production of 
VEGF and improves oxygenation to tissues leading to improvement in 
hyperpermeability and diminishes the trigger needed for new vessel formation. 
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MATERIALS  AND  METHODS 
STUDY POPULATION: 
 This study was conducted among 100 patients with Type 2 Diabetes 
Mellitus attending Department of General Medicine  in Govt. Rajaji Hospital, 
Madurai. 
Inclusion criteria: 
 Type 2 DM patients with:  
o Fasting plasma glucose level≥126 mg/dl  
                           or 
o 2-hour  post prandial glucose level >200 mg/dl 
 Patients treated with dietary modification alone or in combination with 
Oral hypoglycemic agents or insulin were also categorized as type 2 DM 
 Patients with Normoalbuminuria, which is defined as a urinary albumin 
excretion rate (UAER) <20 μg/min or  <30 mg/g  in 2 out of 3 tests 
taken within 2–3 months consecutively. 
 Normal Renal function Test 
Exclusion criteria: 
 Age <18 years or >80 years 
 Dyslipidemias  
 Hepatic failure 
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 Renal failure 
 Smokers 
 Thyroid dysfunction 
 Acute systemic infection 
 Exercise 
 On treatment for anemia 
 Pregnancy  
 Malignancies  
 Refractive errors 
 
ANTICIPATED OUTCOME 
Diabetic patients with retinopathy have lower level of hemoglobin and higher 
frequency of anemia. It is suggested that the level of hemoglobin should be 
evaluated periodically in diabetic patients. In type 2 diabetes mellitus Patients  
even with normoalbuminuria, presence of other risk factors such as   anemia, 
high blood pressure, longer duration of diabetes have high incidence of 
Diabetic Retinopathy. 
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DATA COLLECTION: 
 Detailed history 
 Detailed clinical examination. 
 Ophthalmoscopic examination of fundus 
 Hemoglobin examination   
 Measurement of  Blood Pressure 
Laboratory investigations: 
 Hemoglobin estimation 
 Fundus Examination 
 Urine albumin 
 Renal function test 
 Liver function test 
 Lipid profile 
 RBC, PCV 
 Peripheral Smear 
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STUDY PROTOCOL 
This study is done in 100 type 2 diabetes mellitus patients . 
Patients are first performed renal function test and microalbumin in urine. 
Patients with normal renal function test and normoalbuminuria are selected. 
Then they undergo haemoglobin estimation, measurement of blood pressure 
and history of duration of type 2 diabetes mellitus are elicited. 
Now the patient undergoes fundus examination and screening for diabetic 
retinopathy is done. 
Then the prevalence  of diabetic retinopathy and  the predictors of diabetic 
retinopathy in patients with normoalbuminuria are calculated.  
 
DESIGN OF STUDY 
                   Prospective cross sectional study 
     
PERIOD OF STUDY: 
                 JUNE 2014 to AUGUST 2014 
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   CONSENT: 
                     Individual written and informed consent. 
   
ANALYSIS: 
                     SIMPLE STATISTICAL ANALYSIS 
 
CONFLICT OF INTEREST:  
                     NIL 
 
FINANCIAL SUPPORT: 
              NIL 
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RESULTS AND ANALYSIS 
Table 1: Age distribution in the study population ( n= 100) 
 
Age group 
 
Frequency 
 
Percent 
 
18-35 years 
 
13 
 
13 
 
35-50 years 
 
34 
 
34 
 
50-65 years 
 
33 
 
33 
 
65-85 years 
 
20 
 
20 
 
Total 
 
100 
 
100 
 
Comments: About 67% of the study subjects were in the age group of 35-65 
years while the 20% were in the age group 65-85 years. 
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                      Figure 10 : Age distribution in the study population 
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Table 2 : Distribution of gender in the study population (n=100) 
Gender Frequency Percent 
Female 48 48 
Male 52 52 
Total 100 100 
 
Comments: Majority of the study subjects were males (52%) while the 
remaining 48% were females. 
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Figure 11 : Gender distribution of the study population 
 
 
 
 
 
 
 
 
52 48 
Percentage 
Male
Female
95 
 
 
Table 3 : Incidence of Diabetic retinopathy in study population with 
anemia (n = 39 ) 
 
Anemia 
 
Diabetic 
retinopathy 
(Present) 
 
Diabetic 
retinopathy 
(Absent) 
 
Total 
 
< 6 gms 
 
6 
 
4 
 
10 
 
6-8 gms 
 
18 
 
3 
 
21 
 
>8 – 12 gms 
 
6 
 
2 
 
8 
 
Total 
 
30 
 
9 
 
39 
 
Comment : Among the 39 patients with anemia  30  patients have Diabetic 
retinopathy 
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Figure 12 : Diabetic retinopathy Incidence in study population with 
anemia (n = 39 ) 
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Table 4: Incidence of Diabetic retinopathy in study population with 
systemic Hypertension ( n = 30) 
 
 
Hypertension 
 
Diabetic 
retinopathy 
(Present) 
 
Diabetic 
retinopathy 
(Absent) 
 
Total 
 
Stage 1 
 
14 
 
4 
 
18 
 
Stage 2 
 
9 
 
3 
 
12 
 
Total  
 
23 
 
7 
 
30 
 
Comment : Stage 1 Hypertension : 140/90 mmHg – 160/100 mmHg 
            Stage 2 Hypertension : >160/100 mmHg – 180/110 mmHg 
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Figure 13 : Diabetic retinopathy Incidence in study population with 
systemic Hypertension ( n = 30) 
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Table 5: Diabetic retinopathy Incidence with Longer duration of 
Diabetes   in study population ( n = 100) 
 
 
 
Duration 
 
Diabetic 
retinopathy 
(Present) 
 
Diabetic 
retinopathy 
(Absent) 
 
 
Total 
 
<5 years 
 
6 
 
 
50 
 
54 
 
5 – 15 years 
 
18 
 
6 
 
24 
 
>15 years 
 
16 
 
4 
 
20 
 
Total 
 
40 
 
60 
 
100 
 
Comment : Among 100 patients with diabetes 34 patients have diabetic 
retinopathy if duration of diabetes more than 5 years 
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Figure 14 : Diabetic retinopathy Incidence with Longer duration of 
Diabetes   in study population ( n = 100) 
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Table 6: Prevalence of retinopathy in patients with Hb <8 gms, SHT, 
Duration of diabetes > 5 years 
 
 
 
Predictors 
 
Diabetic 
retinopathy 
(Present) 
 
Diabetic 
retinopathy 
(Absent) 
 
 
Total 
 
 
‘p’ value 
  
   Hb < 8 gms 
 
24 
 
7 
 
31 
 
0.021 
 
Systemic 
Hypertension 
 
23 
 
7 
 
30 
 
0.028 
 
Duration>5 
years 
 
34 
 
10 
 
44 
 
0.005 
 
Comment : Prediction of diabetic retinopathy by Hb < 8 gm/dl , Systemic 
hypertension and longer duration of diabetes are statistically significant. 
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Figure 15 :Prevalence of retinopathy in patients with Hb <8 gms, SHT,    
Duration of diabetes > 5 years 
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                               DISCUSSION 
Diabetic retinopathy is a specific microvascular complication related to 
sight threatening problem in diabetes. DR is characterized by progressive 
alterations in microvasculature of retina, leading to hypoperfusion of retina, 
increased vascular permeability and retinal vessels proliferation. 
           Normoalbuminuria does not imply normal renal function. In type 2 
diabetes mellitus, concordance rate with albuminuria and glomerular 
filtration rate is much less when compared to type 1 diabetes mellitus. 
Hence many type 2 diabetes patients may have decreased glomerular 
filtration rate, which itself  is a risk factor for DR without albuminuria. 
            Hence, even in type 2 diabetes patients with normoalbuminuria, 
presence of other predictors like low haemoglobin, systemic hypertension 
and longer duration of diabetes can identify high risk individuals who 
develop diabetic retinopathy. 
            This study was conducted among 100 patients attended Department 
of General Medicine in Government Rajaji Hospital, Madurai. Gender 
distribution was almost equal with 52% were males and 48% were females. 
Most of the study group was in the age group of 35 to 65 years (67%), rest 
of the study group was at age groups 18-35 and 65-85 years(33%). 
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           Anemia of  haemoglobin < 8 grams was present in 31 patients in the 
study group. Out of which 24 patients had diabetic retinopathy which was 
statistically significant with the ‘p’ value of 0.021. 
          Systemic hypertension was seen in 30 patients in the study group. 
Out of which 23 patients had diabetic retinopathy which was statistically 
significant with the ‘p’ value of 0.028. 
          In the study group, 44 patients had more than 5 years duration. Out of 
which 34 patients had diabetic retinopathy which was statistically 
significant with the ‘p’ value of  0.005. 
           Even though type 2 diabetes mellitus patients have 
normoalbuminuria, they may still have diabetic retinopathy. Hence the 
other predictors of diabetic retinopathy like low haemoglobin, systemic 
hypertension, and longer duration of diabetes should be carefully monitored 
in every patient with type 2 diabetes for early identification and efficient 
treatment of diabetic retinopathy.   
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CONCLUSIONS 
               In patients of type 2 DM, inspite of normoalbuminuria diabetic 
retinopathy is very much common. Absence of albuminuria should not be the 
criteria to defer for screening of diabetic retinopathy. Various predictors for the 
determination of DR are the estimated levels of haemoglobin,  diabetes 
duration, and associated systemic hypertension.  
               . Hence, even in type 2 diabetes patients with normoalbuminuria, 
presence of other predictors like low haemoglobin, systemic hypertension and 
longer duration of diabetes can identify high risk individuals who develop 
diabetic retinopathy.                                
               Large number of diabetic individuals could be anemic. Anemia 
identification and treatment will make a great change in the progression of 
diabetic complications like retinopathy. 
               By early identification and timely intervention of diabetic 
retinopathy, many sight threatening complications can be avoided. 
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SUMMARY 
In this study, the level of hemoglobin in DM patients with DR was lower than 
those without DR. The prevalence of anemia was higher in patients with more 
advanced DR. Concerning the exclusion of patients with creatinine more than 
2 mg/dl in our study, lower hemoglobin level in patients with DR compared to 
patients without DR. 
             Qiao et al. in Finland on 1691 DM patients found that the DM patients 
with hemoglobin level lower than 8 mg/dl were two times more likely to 
develop DR . Consistently, we found that anemic DM patients were 2.4 times 
more likely to develop DR. 
              Chronic hyperglycemia is involved in the pathogenesis of anemia by 
mean of creating abnormalities in RBCs, oxidative stress, autonomic 
neuropathy and renal sympathetic denervation. These conditions put the renal 
inerstitium in a hypoxic state and consequently, the production of 
erythropoietin by peri tubular fibroblasts is impaired 
               In type 1 diabetes, the independent risk factor for the development of 
diabetic retinopathy is microalbuminuria.   
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This is not true in case of type 2 diabetes. So it should be noted that 
retinopathic changes may occur in type 2 diabetes inspite of normal 
albuminuria.. 
              There was about 20 to 30 percent estimated prevalence of diabetic 
retinopathy in patients with normal excretion of albumin in urine. But there are 
only limited number of studies to show the predictors and the prevalence of 
DR in such kind of patients with normal albuminuria.  
            Hence, even in type 2 diabetes patients with normoalbuminuria, 
presence of other predictors like low haemoglobin, systemic hypertension and 
longer duration of diabetes can identify high risk individuals who develop 
diabetic retinopathy.                                 
             In our study, the diabetic retinopathy estimated prevalence  in patients 
with normoalbuminuric type  2 diabetes mellitus  is around  40%. Hence in 
normoalbuminuric  type 2 diabetes individuals, presence of other predictors 
like anemia (Hb < 8 gms), systemic hypertension and longer duration of 
diabetes can identify the individuals with diabetic retinopathy which was 
statistically significant in our study.  
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LIMITATIONS OF THE STUDY 
1. Our study has smaller study group. 
2.More studies are further needed to identify the predictors and the prevalence 
of diabetic retinopathy in type 2 diabetes with  normal albumin excretion. 
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                                      PROFORMA 
 
Name: Age/Sex:   Occupation: 
 
Presenting complaints: 
 H/o Blurring of vision, easy fatiguability,etc.. 
 
Past history: 
H/o Type 2 Diabetes mellitus  
 
Clinical examination: 
 
General examination: 
Consciousness, Pallor, jaundice, Clubbing, Lymphadenopathy, 
hydration status 
Vitals: PR,BP,RR,SpO2. 
 
Systemic examination:  
   CVS:  
           RS: 
           ABD  
           CNS: 
 
Laboratory investigations: 
   Hemoglobin estimation 
 
      Fundus Examination 
 
   Urine albumin 
 
      Renal function test 
 
    Liver function test 
 
   Lipid profile 
 
   RBC, PCV 
 
      Peripheral Blood Smear 
 
 
 
  
                               ABBREVIATIONS 
 
AGE- Advanced Glycation End products 
CHD- Coronary Heart Disease 
CSME- Clinically Significant Macular Edema 
DCCT- Diabetes Complications and Control Trial 
DM- Diabetes Mellitus 
DR- Diabetic Retinopathy 
HBA1C- Glycosylated Hemoglobin 
IDF- Indian Diabetes Federation 
PKC- Protein Kinases C 
ROS- Reactive Oxygen Species 
UKPDS- United Kingdom Prospective Diabetes Study 
 
 
 
 
 
 
 
NAME AGE SEX HEMOGLOBIN in gms BLOOD PRESSURE in mmHg DURATION in years DRP
< 6 6 to 8 8 to 12 > 12 NORMAL stage 1 stage 2 <  5 years 5 to 15 >15
RAMAN M 49 5.8 100/70 18 P
PRABU M 53 14 110/80 19 P
SHEELA F 39 7.8 130/80 4 A
KARUPAYEE F 62 6.8 146/94 4 P
MEENA F 53 5.6 112/78 21 P
ARUN M 71 14 112/76 4 A
SUBBIAH M 54 7.5 170/102 3 P
INDHIRANI F 61 15 126/82 23 P
RAJU M 64 10.8 142/94 3 A
GEETHA F 51 14 118/76 18 P
FATHIMA F 34 11.2 120/72 4 P
VASUNDRA F 69 15 124/86 2 A
SABARISH M 45 6.4 148/100 12 P
KOMANAVALL F 33 14.8 112/66 6 A
SIVAKAMI F 60 15 120/84 3 A
PONMALAR F 60 8.8 164/102 14 P
MURUGESAN M 61 14 114/84 23 P
GOPINATH M 49 5.8 116/74 4 A
MANIKANDAN M 64 15 122/76 21 P
YAZHINI F 58 14.8 118/82 3 A
SENTHIL M 72 7.8 156/98 13 P
ANNAMALAI M 68 14.4 122/68 4 P
NILA F 69 7.2 144/96 13 P
MANICKAM M 43 15 114/76 4 A
PAPPA F 60 14 122/86 9 A
HYDER ALI M 66 15.6 118/66 22 P
CHINNASAMI M 41 14 118/82 2 A
LAVANYA F 55 6.8 172/106 12 P
RAMANI M 40 15 116/86 4 A
GURU M 39 15 120/80 4 A
KIRUBA M 71 14.8 110/86 16 A
AISHWARYA F 46 15 120/82 4 A
MURUGESWAR F 49 15 110/68 3 A
SAMPATH M 55 6.6 152/94 11 P
ISMAIL M 38 14 122/64 12 A
VELLAMMAL F 68 15 118/84 3 A
VASU M 49 5.8 122/68 4 A
SRINI M 31 7.8 174/106 13 P
CHIDABARAM M 56 7 148/98 9 P
MARI M 30 14 110/82 17 A
SETHU M 61 15 110/64 4 A
THENMOZHI F 41 14 122/78 2 A
DURAI M 46 5 150/98 21 P
PUSPAM F 56 6.8 122/86 4 A
KAYAL F 57 6.6 142/94 12 P
KARTHI M 34 15 116/78 3 A
CHITHRA F 71 11 178/102 4 A
ANANDHI F 43 14 112/78 3 A
VEENA F 34 11.8 124/78 4 P
GAYATHRI F 45 15 116/82 3 A
DHANAPAL M 72 14 122/74 4 A
MAHESH M 70 15 132/84 3 A
RAM M 62 10 166/104 14 P
PREMA F 42 7.6 150/98 4 P
VIDHYA F 49 15 128/74 3 A
KAVIARASU M 34 14 114/68 6 A
VALLI F 41 15 134/76 4 A
GOWRI F 44 15 132/84 3 A
MADHESWARI F 72 7.4 122/68 16 P
SHAHJAHAN M 33 6.8 176/108 7 P
ILAVARASI F 42 14 134/68 4 A
PERUMAL M 55 15 122/78 3 A
MYTHILI F 41 15.4 112/82 4 A
PREM M 57 15 132/86 3 A
KAVITHA F 43 14.8 124/68 4 A
GUNA M 47 7.2 142/96 14 P
SHENBAGAM F 64 14 132/84 4 A
CHELLIAH M 59 15 110/68 4 A
THANGAM F 44 15 120/84 3 A
SENGOTTUVEL M 58 5.6 154/92 19 P
ANAND M 72 15 150/98 4 A
PANDI M 69 5.8 120/68 23 P
VAIRAVEL M 72 9 132/68 19 P
NANCY F 36 15 122/68 3 A
NEELAMMAL F 52 14 174/102 4 A
BABU M 69 15 124/88 18 P
SAILAJA F 39 14 132/78 3 A
GOMATHI F 37 15 112/66 4 A
KUPPAMMAL F 54 7.4 122/68 3 A
PERIYASAMY M 64 6.8 150/98 17 P
MUTHAMMAL F 44 15 132/66 16 P
PAPPATHI F 41 14 122/66 14 A
RAJIV M 32 15 118/78 4 A
GEETHA F 67 14 122/64 7 A
KANNAN M 34 5.6 112/84 3 A
PRABAKAR M 34 9 166/108 6 P
VELLAIAMMAL F 59 7 142/92 12 P
PECHI F 66 15 120/84 4 A
LINGAM M 67 15 112/86 4 A
DIVAKAR M 40 7.6 174/106 13 P
SOORI M 58 5 112/68 14 P
DIVYA F 43 14 112/68 3 A
MURUGAN M 51 15 110/88 4 A
RAJI F 44 15 114/84 3 A
DINESH M 53 15 144/98 4 A
SUNDAR M 69 14 178/104 19 A
KALYANI F 31 15 150/96 3 A
VIJAY M 63 5.8 118/84 4 A
MARUTHU M 34 6.6 142/98 7 P
LEELA F 40 15 176/102 9 P

  
  
 
 
